A Phase 1 Study of BAL0891 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced Solid Tumors
Latest Information Update: 23 Apr 2024
At a glance
- Drugs BAL 0891 (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Basilea Pharmaceutica; SillaJen Biotherapeutics
- 17 Apr 2024 Planned primary completion date changed from 24 Sep 2024 to 3 Jul 2025.
- 15 Oct 2023 Trial design, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
- 19 Mar 2023 Planned End Date changed from 24 Nov 2024 to 24 Mar 2026.